Bicycle Therapeutics (NASDAQ:BCYC) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Bicycle Therapeutics (NASDAQ:BCYC) issued its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10, Briefing.com reports. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company’s revenue was down 30.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.16) earnings per share.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $11.32 on Thursday. Bicycle Therapeutics has a 52-week low of $10.91 and a 52-week high of $28.67. The company has a 50-day simple moving average of $13.35 and a two-hundred day simple moving average of $19.46. The company has a market capitalization of $781.65 million, a price-to-earnings ratio of -3.44 and a beta of 0.93.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, COO Alistair Milnes sold 4,578 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $64,504.02. Following the sale, the chief operating officer now directly owns 100,724 shares in the company, valued at $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin Lee sold 9,038 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the completion of the sale, the chief executive officer now owns 495,026 shares in the company, valued at $6,974,916.34. This represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BCYC shares. Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. B. Riley reduced their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Stephens restated an “equal weight” rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.14.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.